Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1967 1
1972 2
1973 1
1974 2
1975 2
1976 1
1977 1
1989 1
1990 1
1992 1
1994 1
1995 2
1996 3
1997 2
1998 2
1999 1
2001 1
2002 2
2003 3
2005 2
2006 1
2007 1
2008 2
2009 1
2010 1
2011 2
2012 3
2013 2
2014 1
2015 4
2016 3
2017 5
2018 3
2019 6
2020 3
2021 5
2022 2
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Update on the management of status epilepticus.
Rossetti AO, Alvarez V. Rossetti AO, et al. Curr Opin Neurol. 2021 Apr 1;34(2):172-181. doi: 10.1097/WCO.0000000000000899. Curr Opin Neurol. 2021. PMID: 33664203 Review.
The recently published ESETT trial provides high-level evidence regarding the equivalence of fosphenytoin, valproate, and levetiracetam as a second-line option. Myoclonus or epileptiform transients on electroencephalography occur in up to 1/3 of patients surviving a cardia …
The recently published ESETT trial provides high-level evidence regarding the equivalence of fosphenytoin, valproate, and levetiracetam as a …
Hashimoto's encephalopathy : epidemiology, pathogenesis and management.
Mocellin R, Walterfang M, Velakoulis D. Mocellin R, et al. CNS Drugs. 2007;21(10):799-811. doi: 10.2165/00023210-200721100-00002. CNS Drugs. 2007. PMID: 17850170 Review.
The clinical presentation may involve a relapsing and remitting course and include seizures, stroke-like episodes, cognitive decline, neuropsychiatric symptoms and myoclonus. ...
The clinical presentation may involve a relapsing and remitting course and include seizures, stroke-like episodes, cognitive decline, …
International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions.
Riney K, Bogacz A, Somerville E, Hirsch E, Nabbout R, Scheffer IE, Zuberi SM, Alsaadi T, Jain S, French J, Specchio N, Trinka E, Wiebe S, Auvin S, Cabral-Lim L, Naidoo A, Perucca E, Moshé SL, Wirrell EC, Tinuper P. Riney K, et al. Epilepsia. 2022 Jun;63(6):1443-1474. doi: 10.1111/epi.17240. Epub 2022 May 3. Epilepsia. 2022. PMID: 35503725
We use language consistent with current accepted epilepsy and seizure classifications and incorporate knowledge from advances in genetics, electroencephalography, and imaging. ...
We use language consistent with current accepted epilepsy and seizure classifications and incorporate knowledge from advances in gene …
Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies.
Hamed SA. Hamed SA. Expert Rev Clin Pharmacol. 2019 Jan;12(1):61-90. doi: 10.1080/17512433.2019.1555468. Epub 2019 Jan 11. Expert Rev Clin Pharmacol. 2019. PMID: 30501441 Review.
Areas covered: This review summarized central and peripheral nervous system complications of uremic syndrome of CKD and their pathogenic mechanisms. They include cognitive deterioration, encephalopathy, seizures, asterixis, myoclonus, restless leg syndrome, central …
Areas covered: This review summarized central and peripheral nervous system complications of uremic syndrome of CKD and their pathogenic mec …
Neuroprognostication in the Post Cardiac Arrest Patient: A Canadian Cardiovascular Society Position Statement.
Primary Panel; Fordyce CB, Kramer AH, Ainsworth C, Christenson J, Hunter G, Kromm J, Lopez Soto C, Scales DC, Sekhon M, van Diepen S, Dragoi L, Josephson C, Kutsogiannis J, Le May MR, Overgaard CB, Savard M, Schnell G, Wong GC, Belley-Côté E; Secondary Panel; Fantaneanu TA, Granger CB, Luk A, Mathew R, McCredie V, Murphy L, Teitelbaum J. Primary Panel, et al. Can J Cardiol. 2023 Apr;39(4):366-380. doi: 10.1016/j.cjca.2022.12.014. Can J Cardiol. 2023. PMID: 37028905
Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to evaluate the evidence underlying factors or diagnostic modalities available to determine prognosis, recommendations were generated in the following domains: (1) circumstances immediatel …
Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to evaluate the evidence underlying factors or d …
Physiology-Based Treatment of Myoclonus.
Pena AB, Caviness JN. Pena AB, et al. Neurotherapeutics. 2020 Oct;17(4):1665-1680. doi: 10.1007/s13311-020-00922-6. Neurotherapeutics. 2020. PMID: 32910414 Free PMC article. Review.
Myoclonus can cause significant disability for patients. Myoclonus has a strikingly diverse array of underlying etiologies, clinical presentations, and pathophysiological mechanisms. ...Levetiracetam, valproic acid, and clonazepam are often used to treat cortical …
Myoclonus can cause significant disability for patients. Myoclonus has a strikingly diverse array of underlying etiologies, cl …
Treatment of myoclonus.
Caviness JN. Caviness JN. Neurotherapeutics. 2014 Jan;11(1):188-200. doi: 10.1007/s13311-013-0216-3. Neurotherapeutics. 2014. PMID: 24037428 Free PMC article. Review.
Levetiracetam is suggested as first-line treatment for cortical myoclonus, but valproic acid and clonazepam are commonly used. Cortical-subcortical myoclonus is the physiology demonstrated by myoclonic seizures, such as in primary epileptic myoclonus ( …
Levetiracetam is suggested as first-line treatment for cortical myoclonus, but valproic acid and clonazepam are commonly used. Cortic …
Management of epilepsy with eyelid myoclonia: Results of an international expert consensus panel.
Smith KM, Wirrell EC, Andrade DM, Choi H, Trenité DK, Jones H, Knupp KG, Mugar J, Nordli DR Jr, Riva A, Stern JM, Striano P, Thiele EA, Zawar I. Smith KM, et al. Epilepsia. 2023 Sep;64(9):2342-2350. doi: 10.1111/epi.17682. Epub 2023 Jun 23. Epilepsia. 2023. PMID: 37326215
OBJECTIVE: There are limited data about the treatment and management of epilepsy with eyelid myoclonia (EEM). The objective of this study was to determine areas of consensus among an international panel of experts for the management of EEM (formerly known as Jeavons …
OBJECTIVE: There are limited data about the treatment and management of epilepsy with eyelid myoclonia (EEM). The objective of …
Cancer pain management.
Bruera E, Lawlor P. Bruera E, et al. Acta Anaesthesiol Scand. 1997 Jan;41(1 Pt 2):146-53. doi: 10.1111/j.1399-6576.1997.tb04629.x. Acta Anaesthesiol Scand. 1997. PMID: 9061098 Review.
As a result of increased opioid exposure, patients are currently developing newer toxicities, mostly central excitability including delirium, myoclonus, grand mal seizures, and hyperalgesia. The observation that more than 80% of patients will require alternate route …
As a result of increased opioid exposure, patients are currently developing newer toxicities, mostly central excitability including delirium …
Drug Treatment of Progressive Myoclonic Epilepsy.
Holmes GL. Holmes GL. Paediatr Drugs. 2020 Apr;22(2):149-164. doi: 10.1007/s40272-019-00378-y. Paediatr Drugs. 2020. PMID: 31939107 Free PMC article. Review.
The progressive myoclonic epilepsies (PMEs) represent a rare but devastating group of syndromes characterized by epileptic myoclonus, typically action-induced seizures, neurological regression, medically refractory epilepsy, and a variety of other signs and symptoms …
The progressive myoclonic epilepsies (PMEs) represent a rare but devastating group of syndromes characterized by epileptic myoclonus, …
85 results